Gastroprotective Efficacy of Rebamipide in Patients With Atrial Fibrillation Treated With DOACs

The goal of this clinical trial is to learn if Rebamipide effective in gastroprotection in patients with atrial fibrillation who are treated with Direct Oral Anticoagulants (DOACs). Another point is to compare efficacy of Rebamipide and of its combination with Pantoprazole with efficacy of Pantoprazole only. Participants will: Take one of three variants of treatments for up to 24 weeks. Visits to the clinic wil take place for screening and then every 8 weeks.

NCT Number	NCT07354230
Lead Sponsor	Pirogov Russian National Research Medical University
Conditions	Atrial Fibrillation (AF)
Enrollment	210 participants
Start Date	2022-01-11
Primary Completion	2024-09-20 (estimated)
Study Completion	2024-09-20 (estimated)
Updated on ClinicalTrials.gov	2026-01-21